Elevance Health Reports Second Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Elevance (ELV) PT Raised to $585 at RBC Capital
July 18, 2024 6:13 AM EDTRBC Capital analyst Ben Hendrix raised the price target on Elevance (NYSE: ELV) to $585.00 (from $575.00) while maintaining a Outperform rating.
The analyst comments "We believe ELV shares are oversold on known temporary Medicaid mix headwinds (which should ease over the next 612 months) and DCP optics... More
Morgan Stanley Reiterates Overweight Rating on Elevance (ELV)
July 17, 2024 8:28 AM EDTMorgan Stanley analyst Erin Wright reiterated an Overweight rating and $643.00 price target on Elevance (NYSE: ELV).
The analyst comments "Pre-Call View - ELV Shares Should Grind higher on Consolidated MLR Beat: While we await conf. call granularity on underlying cost trends by line of business, however, the... More
Truist Securities Reiterates Buy Rating on Elevance (ELV)
July 17, 2024 8:28 AM EDTTruist Securities analyst David MacDonald reiterated a Buy rating and $620.00 price target on Elevance (NYSE: ELV).
The analyst comments "First Read Solid 2Q With MLR A Bit Better, Strong Growth At Carelon, FY Guidance Reaffirmed. ELV reported solid 2Q results featuring in-line revenues, MLR that was modestly better than our/consensus estimates and adjusted EPS also topped expectations with FY guidance of at least $37.20 reaffirmed. Operating revenue of $43.22B was roughly in-line with our $43.24BE and consensus $43.05B... More
